Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

COVID-19

Free Subscription 20.10.2025 1 AJR Am J Roentgenol 1 Infect Control Hosp Epidemiol 1 Int J Infect Dis 1 J Infect 3 J Med Virol 3 J Virol 1 JAMA 7 Lancet 2 Lancet Infect Dis

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. LITTLE BP
   Imaging and Reporting of Post-COVID-19 Lung Abnormalities at CT: International Panel of Experts Provides Welcome Guidance.
   AJR Am J Roentgenol. 2025 Oct 15. doi: 10.2214/AJR.25.33999.
   PubMed        
   
   

   
   Infect Control Hosp Epidemiol

2. ELHAISSOUNI N, Arthur A, Prochaska EC, Colantuoni E, et al
   Association of pandemic precautions and Staphylococcus aureus in the NICU.
   Infect Control Hosp Epidemiol. 2025 Oct 13:1-3. doi: 10.1017/ice.2025.10319.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. OPPONG AE, Coelewij L, Hutchinson M, Carpenter B, et al
   Simple hyperinflammation scores predict mortality in hospitalised patients with COVID-19 and offer a personalised medicine approach to dexamethasone intervention.
   Int J Infect Dis. 2025 Oct 13:108119. doi: 10.1016/j.ijid.2025.108119.
   PubMed         Abstract available
   
   

   
   J Infect

4. TANG X, Ma T, Yao Z, Zhang L, et al
   The triumvirate of mutation bias, population dynamics, and natural selection in shaping SARS-CoV-2 intra-host variation.
   J Infect. 2025;91:106628.
   PubMed        
   
   

   
   J Med Virol

5. GAKLIK LTA, Carneiro BM
   Assessing Influenza and SARS-CoV-2 Coinfection in Brazil: A Comprehensive Study of Patient Outcomes From 2020 to 2023.
   J Med Virol. 2025;97:e70639.
   PubMed         Abstract available
   
   
6. PARRY RH, Shang Y, Sng JDJ, McMillan CLD, et al
   Vaccine-Induced and Hybrid Immunity Against SARS-CoV-2 Variants of Concern in Two Cohorts in Queensland, Australia (2021-2022).
   J Med Virol. 2025;97:e70642.
   PubMed         Abstract available
   
   
7. CHEN W, Li J, Bai S, Zhang A, et al
   Kinetics of IgA Subtypes and Cytokines in Respiratory Secretions Following Immunization With COVID-19 Mucosal Vaccine.
   J Med Virol. 2025;97:e70638.
   PubMed         Abstract available
   
   

   
   J Virol

8. DING S, Yang D, Ullah I, Niu L, et al
   Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants.
   J Virol. 2025 Oct 13:e0103425. doi: 10.1128/jvi.01034.
   PubMed         Abstract available
   
   
9. DADONAITE B, Harari S, Larsen BB, Kampman L, et al
   Spike mutations that affect the function and antigenicity of recent KP.3.1.1-like SARS-CoV-2 variants.
   J Virol. 2025 Oct 13:e0142325. doi: 10.1128/jvi.01423.
   PubMed         Abstract available
   
   
10. YU J, Sun Q, Zhu J, Cui Y, et al
    The integrin protein ITGbeta1 effectively suppresses porcine epidemic diarrhea virus replication through facilitating MDA5 oligomerization and subsequent activation of the type I interferon signaling pathway.
    J Virol. 2025 Oct 17:e0155325. doi: 10.1128/jvi.01553.
    PubMed         Abstract available
    
    

    
    JAMA

11. SAUGEL B, Meidert AS, Brunkhorst FM, Bischoff R, et al
    Individualized Perioperative Blood Pressure Management in Patients Undergoing Major Abdominal Surgery: The IMPROVE-multi Randomized Clinical Trial.
    JAMA. 2025 Oct 12:e2517235. doi: 10.1001/jama.2025.17235.
    PubMed         Abstract available
    
    

    
    Lancet

12. THE LANCET
    Health progress in a post-COVID-19 world.
    Lancet. 2025 Oct 12:S0140-6736(25)01947-6. doi: 10.1016/S0140-6736(25)01947.
    PubMed        
    
    
13. 
    Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01917-8. doi: 10.1016/S0140-6736(25)01917.
    PubMed         Abstract available
    
    
14. 
    Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01330-3. doi: 10.1016/S0140-6736(25)01330.
    PubMed         Abstract available
    
    
15. 
    Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Stud
    Lancet. 2025 Oct 12:S0140-6736(25)01637-X. doi: 10.1016/S0140-6736(25)01637.
    PubMed         Abstract available
    
    
16. REHM J, Assanangkornchai S, Hendershot CS, Franklin A, et al
    Alcohol use disorders.
    Lancet. 2025 Oct 9:S0140-6736(25)01496-5. doi: 10.1016/S0140-6736(25)01496.
    PubMed         Abstract available
    
    
17. RANDERATH W, Grote L, Stenlof K, Fietze I, et al
    Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial.
    Lancet. 2025 Oct 9:S0140-6736(25)01196-1. doi: 10.1016/S0140-6736(25)01196.
    PubMed         Abstract available
    
    
18. NDEMBI N, Mercy K, Folayan MO, Abdool Karim SS, et al
    Analysis of mpox in Angola conflates distinct timelines.
    Lancet. 2025;406:e29.
    PubMed        
    
    

    
    Lancet Infect Dis

19. SCHILLING WHK, Jittamala P, Wongnak P, Watson JA, et al
    Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Lancet Infect Dis. 2025 Oct 10:S1473-3099(25)00482.
    PubMed         Abstract available
    
    
20. HONG CM, Hung IFN
    Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment.
    Lancet Infect Dis. 2025 Oct 10:S1473-3099(25)00549.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO COVID-19 is free of charge.